WELCOME10 TO GET A DISCOUNT ON YOUR FIRST ORDER
RETATRUTIDE
Promotes significant weight loss by reducing appetite, increasing energy expenditure and improving glycaemic control. Notable for achieving significant fat reduction while preserving muscle mass.
Description
Developed by Eli Lilly, Retatrutide is a triple agonist- meaning it simultaneously activates GLP-1, GIP, and glucagon receptors.
This multi-receptor strategy sets it apart from previous generations of weight loss drugs by addressing not just hunger and insulin regulation, but also energy expenditure and fat oxidation.
Early data shows that Retatrutide may be the most powerful obesity treatment ever studied in humans, achieving up to 24.2% body weight loss in less than a year- a number that outpaces both Semaglutide and Mounjaro in head-to-head comparisons.
A Peptide capable of delivering profound weight loss while supporting glycemic control and preserving muscle- a rare combination in obesity pharmacology.
